VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Domestic HER2 ADC Trastuzumab Rezetecan Wins Positive Phase III Results, Filling a Treatment Gap in Refractory Colorectal Cancer
Domestic HER2 ADC Trastuzumab Rezetecan Wins Positive Phase III Results, Filling a Treatment Gap in Refractory Colorectal Cancer
May 29, 2026 17:30 CST Updated May 30, 03:13
Share:
